TR115 / Tarapeutics Science - LARVOL DELTA

TR115 in ARID1A-Mutated Advanced Solid Tumors (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Tarapeutics Science Inc.

New P2 trial • Bladder Cancer • Clear Cell Carcinoma • Endometrial Cancer • Gastric Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Solid Tumor • ARID1A

PHASE I STUDY OF TR115, A NOVEL SELECTIVE EZH2 INHIBITOR, IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AND ADVANCED SOLID TUMORS (EHA 2026) - P1 | "These data support further evaluation of TR115 as monotherapy and in rational combination regimens. (NCT05650580)"

Metastases • P1 data • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Dyslipidemia • Extranodal Natural Killer/T-cell Lymphoma • Hematological Malignancies • Hypertriglyceridemia • Infectious Disease • Leukopenia • Lymphoma • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • Solid Tumor • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • ALK • EZH2

TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma (clinicaltrials.gov) - P3 | N=180 | Not yet recruiting | Sponsor: Tarapeutics Science Inc.

New P3 trial • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A PHASE I STUDY OF AN ORAL EZH2 INHIBITOR TR115 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMAS (ICML 2025) - P1 | "TR115 exhibited a favorable safety profile and promising efficacy in patients with relapsed or refractory non-Hodgkin's lymphoma, particularly in those with relapsed/refractory PTCL. These findings warrant further investigation of TR115. Clinical Study Information: NCT05650580."

Clinical • P1 data • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • EZH2

A phase I study of the EZH2 inhibitor TR115 in patients with relapsed/refractory non-Hodgkin's lymphomas and advanced solid tumors. (ASCO 2025) - P1 | "In this study, TR115 exhibited a favorable safety profile and promising efficacy in patients with relapsed/refractory non-Hodgkin's lymphoma, especially in relapsed/refractory PTCL patients. Further investigation of TR115 alone or in key therapeutic combinations is warranted. (NCT05650580)."

Clinical • Metastases • P1 data • Anemia • B Cell Lymphoma • Breast Cancer • Cutaneous T-cell Lymphoma • Dermatology • Diffuse Large B Cell Lymphoma • Dyslipidemia • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hepatology • Hypertriglyceridemia • Infectious Disease • Leukopenia • Lymphoma • Marginal Zone Lymphoma • Mycosis Fungoides • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Peripheral T-cell Lymphoma • Respiratory Diseases • Solid Tumor • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • ALK

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Recruiting | Sponsor: Tarapeutics Science Inc. | Trial completion date: Jan 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Metastases • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Recruiting | Sponsor: Tarapeutics Science Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Not yet recruiting | Sponsor: Tarapeutics Science Inc.

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor